# EYSUVIS - (0.25% ; SUSPENSION/DROPS)

| | | | |
|---|---|---|---|
| **Generic Name** | LOTEPREDNOL ETABONATE | **Innovator** | Alcon |
| **Dosage** | 0.25% ; SUSPENSION/DROPS | **Branded US Sales** | Less Than $1000 mn |
| **Probable FTF** | None | **Known Para IV Filers** | None |
| **Other ANDA developers** | Less Than 5 | **Tentative Approvals** | None |
| **Final Approvals** | None | **Generic Launches** | None |
| **Indication** | EYSUVIS is a corticosteroid indicated for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. | | |
| **Complexities** | Yes | | |

## Chronology Of Events
Please Contact contact@researchdelta.com to get Detailed Information.

## Executive Summary
Please Contact contact@researchdelta.com to get Detailed Information.

## Patent Status
Please Contact contact@researchdelta.com to get Detailed Information.

## Launch Timelines and Competition
Please Contact contact@researchdelta.com to get Detailed Information.

## Chronology Of Events
Please Contact contact@researchdelta.com to get Detailed Information.